Please Note: This trial is no longer enrolling new participants
A Phase 1/2 FIH Study of REGN5458 (anti-BCMA x anti-CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma
Protocol No. | CTO-R5458-ONC-1826 | Scope | National |
---|---|---|---|
Principal Investigator | Attaya Suvannasankha | Treatment Type | Treatment |
Age Group | Adult | Phase | Phase I/II |